Deals

Predictive Biosciences anatomic pathology business acquired by Miraca Life Sciences November 19, 2012

Overview

Crosstree Capital Partners is pleased to announce the sale of the anatomic pathology division of Predictive Biosciences (“Predictive”) to Miraca Life Sciences (“MLS”).

Based in Cleveland, Ohio and serving clients nationwide, Predictive’s anatomic pathology division specializes in urologic pathology services delivered by top tier pathologists.

Significance

The acquisition bolsters MLS’ existing urologic pathology offering and broadens the company’s subspecialty capabilities.

Crosstree’s Role

Crosstree Capital Partners served as exclusive financial advisor to Predictive Biosciences.

The transaction allowed Predictive to monetize its anatomic pathology business and focus resources on the Company’s proprietary bladder cancer assay.

Sub-Sector

Diagnostics and Tools

Type

Merger and Acquisition

Deal Tags

Cross-border
Diagnostic Laboratory
International client or transaction